Glenmark Life Sciences Limited Stock Bombay S.E.

Equities

GLS

INE03Q201024

Pharmaceuticals

Delayed Bombay S.E. 04:57:43 2024-07-18 am EDT 5-day change 1st Jan Change
849.6 INR -0.52% Intraday chart for Glenmark Life Sciences Limited +0.81% +29.30%
Sales 2024 22.83B 273M Sales 2025 * 25.67B 307M Capitalization 105B 1.25B
Net income 2024 4.71B 56.34M Net income 2025 * 5.47B 65.41M EV / Sales 2024 4.04 x
Net cash position 2024 3.02B 36.09M Net cash position 2025 * 2.5B 29.94M EV / Sales 2025 * 3.98 x
P/E ratio 2024
20.2 x
P/E ratio 2025 *
19.1 x
Employees 1,824
Yield 2024
2.9%
Yield 2025 *
2.57%
Free-Float 23.57%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Glenmark Life Sciences Limited

1 day-1.08%
1 week+0.23%
Current month-2.84%
1 month-1.33%
3 months+5.72%
6 months+11.55%
Current year+28.56%
More quotes
1 week
834.65
Extreme 834.65
867.35
1 month
820.05
Extreme 820.05
970.00
Current year
654.00
Extreme 654
970.00
1 year
597.80
Extreme 597.8
970.00
3 years
369.00
Extreme 369
970.00
5 years
369.00
Extreme 369
970.00
10 years
369.00
Extreme 369
970.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-08-12
Director of Finance/CFO - 22-05-31
Compliance Officer - 21-02-22
Members of the board TitleAgeSince
Director/Board Member 66 20-10-29
Chief Executive Officer 58 19-08-12
Human Resources Officer 49 18-10-10
More insiders
Date Price Change Volume
24-07-18 849.6 -0.52% 7 898
24-07-16 854 +1.18% 11,972
24-07-15 844.1 -0.61% 29,468
24-07-12 849.2 +0.76% 45,704
24-07-11 842.8 -4.11% 30,626

Delayed Quote Bombay S.E., July 18, 2024 at 02:15 am EDT

More quotes
Glenmark Life Sciences Limited is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as anti-fungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of approximately 1198 KL.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
855.1 INR
Average target price
932.6 INR
Spread / Average Target
+9.06%
Consensus